Get the Stockscreener App
8.99
1.24%
0.11
Pre-market:
8.10
-0.89
-9.90%
Gh Research Plc stock is traded at $8.99, with a volume of 107.49K.
It is up +1.24% in the last 24 hours and up +31.24% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$8.88
Open:
$9.03
24h Volume:
107.49K
Relative Volume:
1.50
Market Cap:
$467.73M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-14.50
EPS:
-0.62
Net Cash Flow:
$-36.14M
1W Performance:
+9.77%
1M Performance:
+31.24%
6M Performance:
-18.64%
1Y Performance:
+53.68%
1-Day Range:
$8.5901
$9.33
1-Week Range:
$8.25
$9.33
52-Week Range:
$5.67
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
8.99 | 467.73M | 0 | -32.32M | -36.14M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
GH Research PLC (NASDAQ:GHRS) Sees Large Increase in Short Interest - MarketBeat
How the (GHRS) price action is used to our Advantage - Stock Traders Daily
GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright - Defense World
Cormark Issues Negative Outlook for Hudbay Minerals Earnings - Defense World
What is Zacks Research’s Forecast for HALO Q3 Earnings? - Defense World
Jane Street Group LLC Cuts Stock Holdings in Columbia Research Enhanced Value ETF (NYSEARCA:REVS) - Defense World
Harmonic (NASDAQ:HLIT) Rating Lowered to Equal Weight at Barclays - Defense World
Digital Turbine (NASDAQ:APPS) Shares Cross Above 50 Day Moving Average – Should You Sell? - Defense World
Barclays PLC Purchases Shares of 3,960 American Outdoor Brands, Inc. (NASDAQ:AOUT) - Defense World
Barclays PLC Purchases New Shares in Innovator U.S. Equity Buffer ETF – March (BATS:BMAR) - Defense World
Barclays PLC Invests $40,000 in FT Vest U.S. Equity Deep Buffer ETF – July (BATS:DJUL) - Defense World
Barclays PLC Has $39,000 Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Barclays PLC Boosts Position in CEMEX, S.A.B. de C.V. (NYSE:CX) - Defense World
Barclays PLC Takes Position in Myomo, Inc. (NYSEAMERICAN:MYO) - Defense World
American Realty Investors, Inc. (NYSE:ARL) Shares Bought by Barclays PLC - Defense World
Barclays PLC Increases Stock Holdings in Angi Inc. (NASDAQ:ANGI) - Defense World
GH Research PLC (NASDAQ:GHRS) Shares Sold by Barclays PLC - Defense World
GH Research reports progress in depression treatment trials By Investing.com - Investing.com Australia
GH Research (NASDAQ:GHRS) Earns "Buy" Rating from HC Wainwright - MarketBeat
GH Research says completed all FDA requests to address IND hold - TipRanks
GH Research reports progress in depression treatment trials - Investing.com India
GH Research announces primary endpoint met in two Phase 2a PoC trials - TipRanks
GH Research Achieves Key Milestones in Depression Trials and Prepares FDA Response - TipRanks
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents - The Manila Times
GH Research Announces Primary Endpoint Met in Two Phase 2a - GlobeNewswire
GH Research's Depression Drug Achieves 100% Remission in Postpartum Trial, Advances in Bipolar Study - StockTitan
Cedi To End 2025 Around GH¢17.70 To Dollar – Report - Peace FM Online
Learn to Evaluate (GHRS) using the Charts - Stock Traders Daily
Credibility gap closing for psychedelics - BioWorld Online
GH Research (NASDAQ:GHRS) Trading Down 6.7% – Should You Sell? - Defense World
GH Research (NASDAQ:GHRS) Shares Down 6.7%Should You Sell? - MarketBeat
How To Trade (GHRS) - Stock Traders Daily
CBG secures historic GH¢350m capital raise for Kasapreko PLC - Myjoyonline
Fmr LLC Boosts Stake in Vodafone Group Public Limited (NASDAQ:VOD) - Defense World
Fmr LLC Trims Holdings in GH Research PLC (NASDAQ:GHRS) - MarketBeat
3 Top Cybersecurity Stock Picks for 2025 - Head Topics
GH Research PLC Attends Key Neuropsychopharmacology Conference - TipRanks
RA Capital Management L.P. Has $44.73 Million Stock Position in GH Research PLC (NASDAQ:GHRS) - MarketBeat
GH Research PLC (NASDAQ:GHRS) Shares Sold by Verition Fund Management LLC - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Down 0.3%What's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Up 2%Should You Buy? - MarketBeat
GH Research (NASDAQ:GHRS) Trading Down 0.8%Here's What Happened - MarketBeat
(PDF) Neurotrophic and synaptic effects of GnRH and/or GH upon motor function after spinal cord injury in rats - ResearchGate
GH Research (NASDAQ:GHRS) Stock Price Up 1.4%Here's Why - MarketBeat
GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
(GHRS) Technical Data - Stock Traders Daily
HC Wainwright Reduces Earnings Estimates for GH Research - Defense World
GH Research (NASDAQ:GHRS) Shares Down 5.1%What's Next? - MarketBeat
FY2024 EPS Estimates for GH Research Cut by HC Wainwright - MarketBeat
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? - MSN
GH Research (NASDAQ:GHRS) Trading Down 1.7%Here's What Happened - MarketBeat
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):